Name: Latest research reports of J B Chemicals & Pharmaceuticals Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: J B Chemicals & Pharmaceuticals Ltd.
Rating: 4
Author: ICICI Securities Limited

J B Chemicals & Pharmaceuticals Ltd.

NSE: JBCHEPHARM | BSE: 506943 | ISIN: INE572A01036 | Industry: Pharmaceuticals
| Expensive Performer

1590.3000 68.05 (4.47%)

NSE Mar 18, 2025 15:31 PM

New 52W Low in past week

Volume: 189.7K

J B Chemicals & Pharmaceuticals Ltd.

10 Feb 2023

1590.30

4.47%

In-line performance

Accumulate: J B Chemicals & Pharmaceut...

Target

ICICI Securities Limited

JB Chemicals & Pharmaceuticals (JBCPL) Q3FY23 performance was broadly in line with our estimates, driven by robust growth across the segments. Consolidated revenue grew 32% YoY to Rs7.9bn (I-Sec: 7.7bn) driven by acquisitions in India.

Number of FII/FPI investors increased from 279 to 294 in Dec 2024 qtr.

The Baseline | 18 Mar 2025, 05:17PM

Market closes higher, HUL gets approval to acquire Minimalist's parent firm for Rs 2,670 crore

Trendlyne Marketwatch | 18 Mar 2025, 04:04PM

New leadership, fresh strategy at JB Chemicals sees impact in Q1FY23

| 09 Sep 2022